Guardant Health (NASDAQ:GH) Director Medina Manuel Hidalgo Sells 1,250 Shares of Stock

Guardant Health, Inc. (NASDAQ:GH) Director Medina Manuel Hidalgo sold 1,250 shares of Guardant Health stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $107.09, for a total transaction of $133,862.50. Following the completion of the sale, the director directly owned 1,639 shares in the company, valued at $175,520.51. This represents a 43.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Medina Manuel Hidalgo also recently made the following trade(s):

• On Friday, March 6th, Medina Manuel Hidalgo sold 1,300 shares of Guardant Health stock. The shares were sold at an average price of $91.54, for a total transaction of $119,002.00.

Guardant Health Stock Performance

Guardant Health stock opened at $118.95 on Friday. The company’s fifty day moving average price is $91.15 and its 200 day moving average price is $98.94. Guardant Health, Inc. has a 1 year low of $36.36 and a 1 year high of $121.01. The stock has a market capitalization of $15.77 billion, a P/E ratio of -35.09 and a beta of 1.48.

Guardant Health (NASDAQ:GH) last announced its earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The business had revenue of $281.27 million for the quarter, compared to the consensus estimate of $269.74 million. During the same quarter in the previous year, the business posted ($0.62) earnings per share. The firm’s revenue was up 39.4% compared to the same quarter last year. Sell-side analysts predict that Guardant Health, Inc. will post -2.92 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of GH. AQR Capital Management LLC raised its holdings in shares of Guardant Health by 56.5% during the 1st quarter. AQR Capital Management LLC now owns 71,534 shares of the company’s stock worth $3,012,000 after acquiring an additional 25,831 shares during the period. Empowered Funds LLC purchased a new position in shares of Guardant Health during the 1st quarter worth $274,000. Sei Investments Co. raised its holdings in shares of Guardant Health by 15.8% during the 2nd quarter. Sei Investments Co. now owns 77,308 shares of the company’s stock worth $4,023,000 after acquiring an additional 10,538 shares during the period. The Manufacturers Life Insurance Company raised its holdings in shares of Guardant Health by 9.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 632,630 shares of the company’s stock worth $32,922,000 after acquiring an additional 54,284 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Guardant Health by 56.4% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 111,445 shares of the company’s stock worth $5,800,000 after acquiring an additional 40,209 shares during the period. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Analyst Upgrades and Downgrades

GH has been the topic of several recent research reports. JPMorgan Chase & Co. lifted their target price on shares of Guardant Health from $130.00 to $135.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Citigroup lifted their target price on shares of Guardant Health from $135.00 to $150.00 and gave the stock a “buy” rating in a research note on Friday, February 20th. Robert W. Baird initiated coverage on shares of Guardant Health in a research note on Tuesday, February 17th. They set an “outperform” rating and a $120.00 target price on the stock. Barclays lifted their target price on shares of Guardant Health from $115.00 to $120.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Finally, Evercore set a $110.00 target price on shares of Guardant Health in a research note on Friday, February 20th. Nineteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Guardant Health currently has an average rating of “Moderate Buy” and a consensus target price of $129.00.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.